Brief: United Therapeutics Announces Advance Outcomes Study Of Ralinepag
17/05/2026 19:17
May 17 (Reuters) - United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS CORPORATION ANNOUNCES ADVANCE OUTCOMES STUDY OF RALINEPAG PRESENTED AT ATS 2026 UNITED THERAPEUTICS CORP: PHASE 3 ADVANCE OUTCOMES STUDY MET ITS PRIMARY ENDPOINT Source text: ID:nBw11vXBya Further company coverage: UTHR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug